TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11701070
Drug: Megadose steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megadose steroid therapy (group S)
Study: 11701070
Drug: Lipoprostaglandin E(1)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lipoprostaglandin E(1) therapy (group L)
Study: 9337183
Drug: KCl infusion
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KCl infusion (maximum, 40 mEq) in healthy subjects treated with quinidine sulfate
Study: 9337183
Drug: KCl infusion
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KCl infusion (maximum, 40 mEq) in CHF patients
Study: 7887823
Drug: Filling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filling the dialysis circuit with 6.7% human albumin in saline for 10 min at a flow rate of 100 ml/min before HD
Study: 3126634
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (NTG) 10 mg
Study: 3126634
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (NTG) 5 mg
Study: 30217412
Drug: Oncology rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oncology rehabilitation with motivational interviewing delivered once weekly for 7 weeks via telephone by a physiotherapist
Study: 26187456
Drug: Dronabinol 30
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol 30 mg/d
Study: 23725999
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg/d) with concurrent radiation (60 Gy in 30 fractions) and temozolomide (75 mg/m2 per day)
Study: 20979460
Drug: Acupressure (eight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure (eight treatments over 4 weeks)
Study: 16957130
Drug: Patients on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on dopamine agonists
Study: 16957130
Drug: Patients not
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not specified as on dopamine agonists
Study: 12562338
Drug: Wax epilation
Normalized name: Candelilla Wax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wax epilation followed by long-pulsed alexandrite laser treatment
Study: 7880221
Drug: Active medications
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medications and surgery
Study: 23835718
Drug: Obinutuzumab (GA101)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab (GA101) 1,600/800 mg
Study: 23835718
Drug: Obinutuzumab (GA101)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab (GA101) 400/400 mg
Study: 16958565
Drug: Risperidone (0.25-4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.25-4.5 mg/day, mean dose 1.62 ± 1.02 mg/day)
Study: 16958565
Drug: Olanzapine (2.5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (2.5-20 mg/day, mean dose 8.18 ± 4.41 mg/day)
Study: 16958565
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Risperidone and Olanzapine)
Study: 15041031
Drug: Fatty acid
Normalized name: FATTY ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatty acid treatment
Study: 1791060
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose capsule)
Study: 1645825
Drug: Mixed bacterial
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed bacterial vaccine (MBV) in Series 1
Study: 1645825
Drug: Mixed bacterial
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed bacterial vaccine (MBV) in Series 2
Study: 1645825
Drug: Mixed bacterial
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed bacterial vaccine (MBV)
Study: 28367037
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium diclofenac 0.1%
Study: 24099839
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (200mg immediately after each chemotherapy infusion)
Study: 24099839
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous fumarate (200mg three times a day)
Study: 21341889
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for PTSD and depressive symptoms
Study: 9727727
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg plus Pindolol 7.5 mg
Study: 9727727
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg plus Placebo
Study: 9836512
Drug: Insulin 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin 0.25 mU x kg(‐1) x min(‐1)
Study: 9836512
Drug: Insulin 0.5
Normalized name: Monoject Insulin 0.5mL U-100 Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin 0.5 mU x kg(‐1) x min(‐1)
Study: 9836512
Drug: Insulin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin 1.0 mU x kg(‐1) x min(‐1)
Study: 9836512
Drug: Insulin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (all dosages)
Study: 2501714
Drug: Ferric chondroitin
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric chondroitin sulfate (90 mg of iron)
Study: 2501714
Drug: Ferritin iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferritin iron (91 mg)
Study: 23941549
Drug: Dexmedetomidine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.6 μg/kg/h continuous infusion)
Study: 23941549
Drug: Saline (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.9% sodium chloride for injection, maintenance infusion)
Study: 19396417
Drug: Long-term psychoanalysis
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term psychoanalysis (defined as fewer than 50 treatment sessions)
Study: 15329210
Drug: Pegasys (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegasys (180 microg injection once a week for 24 weeks)
Study: 15329210
Drug: Roferon-A (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roferon-A (3 MU injection three times a week for 24 weeks)
Study: 11367659
Drug: Integrated traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated traditional Chinese and Western medicine (TCM‐WM)
Study: 3535552
Drug: Triple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple dose cefoxitin
Study: 29955115
Drug: Risperidone treatment
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone treatment in ASD patients
Study: 25085771
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (positive control)
Study: 25085771
Drug: Targeted selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted selective treatment (TST)
Study: 11472451
Drug: Repaglinide, 1‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide, 1‐4 mg at mealtimes
Study: 11472451
Drug: Glipizide, 5‐15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide, 5‐15 mg daily
Study: 6451461
Drug: DS 103-282
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS 103-282 (5 mg, three times daily for 7 days)
Study: 6451461
Drug: Diazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (5 mg, three times daily for 7 days)
Study: 27908227
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (10,000 IU soft gels administered three times per week)
Study: 27908227
Drug: Placebo (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vitamin A soft gels devoid of active ingredients administered thrice weekly)
Study: 17479946
Drug: SQV-RTV-ATV regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV-RTV-ATV regimen (1500 mg saquinavir, 100 mg ritonavir, 300 mg atazanavir once per day without NRTIs)
Study: 17479946
Drug: SQV formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV formulations (200 mg vs. 500 mg)
Study: 12365904
Drug: Laser trabeculoplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser trabeculoplasty plus topical betaxolol hydrochloride (n = 129)
Study: 12365904
Drug: No initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No initial treatment (n = 126)
Study: 12365904
Drug: Laser trabeculoplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser trabeculoplasty plus topical betaxolol hydrochloride
Study: 2726279
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg + 20 mg codeine
Study: 820357
Drug: Synthetic thyrotrophin
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic thyrotrophin releasing factor (TRF, Ro 08‐6270) administered via rapid i.v. injection
Study: 30591415
Drug: Alirocumab dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab dose increase (from 75 to 150 mg Q2W)
Study: 26131612
Drug: Liuzijue Qigong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liuzijue Qigong (LQG) program consisting of four 45‐minute sessions each week and daily walking for 30 minutes for 6 months
Study: 26131612
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group walking daily for 30 minutes
Study: 11405514
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (30 mg x day(-1))
Study: 9514183
Drug: MO/HCTZ 3.75/6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MO/HCTZ 3.75/6.25 mg once daily
Study: 30137242
Drug: Protease inhibitor-based
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor-based regimens
Study: 24116356
Drug: MCBA +
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCBA + 5.6 mL of rhBMP‐2/ACS (8.4 mg of rhBMP‐2)
Study: 24116356
Drug: MCBA +
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCBA + 2.8 mL of rhBMP‐2/ACS (4.2 mg of rhBMP‐2)
Study: 21951654
Drug: Single intraarticular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intraarticular injection of 40 mg triamcinolone
Study: 21951654
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections of 40 mg triamcinolone at 21‐day interval
Study: 19469115
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia (TEA) with 10 mL of 0.5% bupivacaine before and at the end of surgery
Study: 19469115
Drug: Thoracic paravertebral
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic paravertebral analgesia (TPVA) with 30 mL of 0.5% bupivacaine before and 15 mL at the end of surgery
Study: 17545082
Drug: Podophyllotoxin solid
Normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Podophyllotoxin solid lipid nanoparticle gel
Study: 17545082
Drug: Routine podophyllotoxin
Normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine podophyllotoxin gel preparation
Study: 8468105
Drug: Carleton Skill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carleton Skill Training Program (CSTP) to increase hypnotic susceptibility
Study: 3514908
Drug: Butoconazole vaginal
Normalized name: butoconazole Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butoconazole vaginal suppositories, 100 mg/day
Study: 3514908
Drug: Clotrimazole vaginal
Normalized name: Clotrimazole Vaginal Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole vaginal tablets, 200 mg/day
Study: 20435293
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of dexketoprofen
Study: 20435293
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL intrauterine 2% lidocaine
Study: 19115153
Drug: Alverine citrate
Normalized name: alverine citrate
DrugBank: Alverine (DB01616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alverine citrate plus simethicone (60 mg alverine citrate + 300 mg simethicone)
Study: 12364840
Drug: Attachment-based family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attachment-based family therapy (ABFT) for 12 weeks
Study: 10472854
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 0.025 mg/day
Study: 10472854
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 0.05 mg/day
Study: 10472854
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 0.06 mg/day
Study: 10472854
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 0.1 mg/day
Study: 8752759
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of pure oxygen (O2) during EIS
Study: 8752759
Drug: No inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No inhalation of pure oxygen (O2) during EIS
Study: 6401230
Drug: Nitroglycerin (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (0.8 mg sublingually)
Study: 6401230
Drug: Metoprolol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (0.15 mg/kg i.v.)
Study: 26773321
Drug: Homeopathic complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic complex (6cH each of Arnica montana, Bryonia alba, Causticum, Kalmia latifolia, Rhus toxicodendron, and Calcarea fluorica) plus standard physiotherapy (massage, thermal therapy, joint mobilization) every 2 weeks
Study: 26773321
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus standard physiotherapy (massage, thermal therapy, joint mobilization) every 2 weeks
Study: 24589127
Drug: Liraglutide plus
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide plus insulin (LIRA)
Study: 24589127
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin only (controls)
Study: 16286056
Drug: Inhaled zanamivir
Normalized name: zanamivir Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled zanamivir 10 mg once daily for 14 days
Study: 7491655
Drug: Acetazolamide (ACZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (ACZ) 1 to 1.6 g intravenously
Study: 1968731
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion (0.05 microgram/kg body weight/minute for 120 minutes) with placebo pretreatment
Study: 1968731
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion with atenolol pretreatment (beta-1-selective blocker)
Study: 1968731
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion with propranolol pretreatment (nonselective beta blocker)
Study: 1968731
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion with ICI 118551 pretreatment (beta-2-selective blocker)
Study: 1968731
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion with different pretreatments
Study: 387542
Drug: Vincristine, methotrexate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine, methotrexate, cyclophosphamide, and 5-fluorouracil (initiation course) followed by mitomycin-C with 5-fluorouracil (maintenance therapy)
Study: 22221684
Drug: IAADS (Improved
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAADS (Improved Anesthetic Agent Delivery System)
Study: 15474248
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C vaginal tablets (250 mg) once a day for 6 days
Study: 15474248
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C vaginal tablets
Study: 8202898
Drug: Flurbiprofen 200
Normalized name: flurbiprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 200 mg
Study: 11121916
Drug: Aspirin 2600
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 2600 mg
Study: 2787809
Drug: Cimetidine and
Normalized name: Cimetidine and sodium alginate only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine and antacids (added after severe injuries)
Study: 557318
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg subcutaneous physostigmine therapy (three sessions)
Study: 557318
Drug: Control injections
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control injections (randomly interspersed sessions)
Study: 31699568
Drug: hs-CRP ≥0.74
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP ≥0.74 mg/L at 3 months
Study: 25497995
Drug: Omalizumab (225-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (225-300 mg every 2 weeks)
Study: 25497995
Drug: Omalizumab (every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (every 4 weeks dosing regimen)
Study: 25497995
Drug: Omalizumab (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (higher or lower doses)
Study: 17351987
Drug: Anthroposophy art
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthroposophy art therapy (painting with water-based paints)
Study: 15353002
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g alcohol per day
Study: 15353002
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g alcohol per day
Study: 29374350
Drug: Nefopam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (20 mg mixed in 100 ml normal saline)
Study: 29374350
Drug: Control (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (100 ml normal saline only)
Study: 23007732
Drug: Clamp-crushing parenchyma
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clamp-crushing parenchyma transection (CC-PT)
Study: 17784972
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) administered over six weekly sessions
Study: 17784972
Drug: Delayed cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed cognitive-behavioural therapy (D-CBT) administered twice weekly over three weeks
Study: 14996630
Drug: Oral antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antiplatelet and antithrombotic therapies
Study: 12056242
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy using five different protocols
Study: 9931764
Drug: Electrostimulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrostimulation therapy
Study: 2686259
Drug: 4 mg/h
Normalized name: estradiol 0.00104 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/h of ISDN
Study: 27859533
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment-based approach (ART-based)
Study: 25727953
Drug: 0.5‐h infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5‐h infusion of 0.5 g of imipenem every 6 h for 8 doses
Study: 25727953
Drug: 4‐h infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐h infusion of 0.5 g of imipenem every 6 h for 8 doses
Study: 25727953
Drug: 4‐h infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐h infusion of 1 g of imipenem every 6 h
Study: 25727953
Drug: 0.5‐h infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5‐h infusion of 1 g of imipenem every 6 h
Study: 25727953
Drug: All simulated
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All simulated regimens (4‐h infusion)
Study: 23478070
Drug: Lansoprazole (LPZ)
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole (LPZ) 15mg once daily
Study: 23478070
Drug: Gefarnate (GFN)
Normalized name: Guaifenesin
DrugBank: Gefarnate (DB12079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefarnate (GFN) 50mg twice daily
Study: 19317378
Drug: Ramelteon 8
Normalized name: ramelteon 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon 8 mg at bedtime for 10 weeks
Study: 19317378
Drug: Ramelteon 8
Normalized name: ramelteon 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon 8 mg at bedtime
Study: 17162041
Drug: Pelvicol porcine
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pelvicol porcine collagen implant
Study: 17162041
Drug: No implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No implant (control group)
Study: 7843479
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (elemental calcium 156 or 312 mg/day per os) and vitamin D3 (0.5 micrograms/3 day per os)
Study: 25772974
Drug: Web-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based intervention (PA website and monthly tailored emails)
Study: 25772974
Drug: Mixed intervention
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed intervention (combination of web- and center-based)